For complete information about the report, please visit our website
https://www.reportscorner.com/reports/28650/CADILA-HEALTHCARE-,--Lipaglyn-Launched-in-India-%E2%80%93-Survey-suggests-quick-market-acceptance,-if-priced-appropriately/
Zydus today announced the launch of its novel dual PPAR agonist Lipaglyn (saroglitazar) for treatment of diabetic dyslipidemia patients not controlled by statin alone. Based on our physician survey / assessment of the drug profile / market analysis, we expect Lipaglyn to garner around INR 650 million in peak sales in India by 2016. We see the need of a fixed dose combination of Lipaglyn with statin as important for the quick ramp up for this novel compound.
https://www.reportscorner.com/reports/28650/CADILA-HEALTHCARE-,--Lipaglyn-Launched-in-India-%E2%80%93-Survey-suggests-quick-market-acceptance,-if-priced-appropriately/
Zydus today announced the launch of its novel dual PPAR agonist Lipaglyn (saroglitazar) for treatment of diabetic dyslipidemia patients not controlled by statin alone. Based on our physician survey / assessment of the drug profile / market analysis, we expect Lipaglyn to garner around INR 650 million in peak sales in India by 2016. We see the need of a fixed dose combination of Lipaglyn with statin as important for the quick ramp up for this novel compound.
No comments:
Post a Comment